According to Gram Research analysis, romosozumab increased spine bone density by 11.5% and hip bone density by 4.1% in 22 postmenopausal women with breast cancer-related bone loss after 12 months of treatment. No new fractures or cancer recurrence occurred during follow-up, suggesting the drug may help strengthen bones in breast cancer patients whose bones have weakened from hormone therapy, though larger studies are needed to confirm safety and effectiveness.
Breast cancer patients taking certain hormone treatments often develop weak bones as a side effect. Researchers tested a new drug called romosozumab on 22 postmenopausal women with this problem. After one year of treatment, patients’ spine bones became 11.5% denser and hip bones became 4.1% denser. The good news: no patients broke bones or had cancer come back during the study. However, because this was a small study without a comparison group, doctors need larger studies to confirm these results are safe and effective.
Key Statistics
A 2026 case series of 22 postmenopausal women found that romosozumab increased lumbar spine bone density by 11.5% after 12 months of treatment for cancer treatment-induced bone loss.
In a 2026 study of 22 breast cancer patients receiving romosozumab, total hip bone density increased by 4.1% over 12 months, with no new fractures observed during the treatment period.
A 2026 case series of 22 postmenopausal women with hormone receptor-positive breast cancer showed stable cancer markers and no clinical evidence of cancer recurrence during a mean follow-up of 38 months while receiving romosozumab for bone loss.
The Quick Take
- What they studied: Whether a new drug called romosozumab could help strengthen bones in breast cancer patients whose bones became weak from cancer treatment
- Who participated: 22 postmenopausal women (average age 67) with hormone receptor-positive breast cancer who had been taking aromatase inhibitor therapy for about 3 years and developed bone loss
- Key finding: After 12 months of romosozumab treatment, spine bone density increased by 11.5% and hip bone density increased by 4.1%, with no new fractures or cancer recurrence observed during follow-up
- What it means for you: This drug may help breast cancer patients rebuild bone strength when other treatments haven’t worked well enough, but larger studies are needed before doctors can confidently recommend it as standard treatment
The Research Details
This was a retrospective case series, meaning researchers looked back at medical records of 22 women who had already received romosozumab treatment at one hospital. The women received the drug for 12 months because they either had progressive bone loss, new fractures, or were at high risk for breaking bones. Researchers measured bone density at the spine and hip before and after treatment, tracked bone turnover markers (signs of bone activity), and monitored cancer markers in the blood.
The study followed patients for an average of 38 months total, including the 12-month treatment period. All patients also received calcium and vitamin D supplements alongside the romosozumab. The researchers compared how well the drug worked in women who had never taken bone-strengthening drugs before versus those who had.
This research approach is important because it provides real-world evidence of how romosozumab performs in actual cancer patients, not just in laboratory settings. However, because it’s a small study looking backward at existing records without a control group for comparison, the findings are preliminary and need confirmation through larger, prospective studies where researchers follow patients forward in time.
Strengths: This study provides the first clinical data on romosozumab in breast cancer patients and shows promising bone density improvements. Weaknesses: The sample size is very small (22 patients), there’s no comparison group to show whether romosozumab works better than other treatments, the study is retrospective (looking back), and follow-up time is relatively short for assessing cancer safety. The authors themselves emphasize these limitations and call for larger studies.
What the Results Show
After 12 months of romosozumab treatment, patients showed significant improvements in bone density. Lumbar spine bone density (the lower back) increased by 11.5%, which was statistically significant. Total hip bone density increased by 4.1%, also statistically significant. These improvements occurred in women who had been experiencing progressive bone loss despite being on other treatments.
During the 12-month treatment period, no patients experienced new fragility fractures (breaks from minor falls or bumps). This is important because bone loss from cancer treatment typically increases fracture risk. The bone turnover markers changed in ways consistent with how romosozumab is supposed to work—it slows bone breakdown while promoting bone formation.
Cancer markers in the blood (CA15-3 and CEA) remained stable throughout treatment and follow-up. No patients showed clinical evidence of cancer recurrence during the mean follow-up period of 38 months. The drug appeared to work similarly well in patients who had never taken bone-strengthening drugs before and those who had prior exposure to other bone-modifying agents, though the small sample size limits firm conclusions about this comparison.
Romosozumab has previously been proven effective for osteoporosis in postmenopausal women without cancer. This is the first case series showing it may also help breast cancer patients with treatment-induced bone loss. Most breast cancer patients with bone loss currently receive antiresorptive agents (drugs that slow bone breakdown), but some continue losing bone or breaking bones anyway. Romosozumab works differently—it stimulates bone formation in addition to slowing breakdown—which may explain why it helped these patients.
The study is small (only 22 patients), making it hard to draw firm conclusions. There’s no control group, so we can’t compare romosozumab to other treatments or to no treatment. The study is retrospective, relying on existing medical records rather than carefully controlled prospective data collection. Follow-up time is relatively short for assessing long-term safety in cancer patients. The study was conducted at a single institution, which may not represent all patient populations. Most importantly, the sample size is too small to confidently assess rare but serious side effects or long-term cancer safety.
The Bottom Line
Based on this preliminary evidence, romosozumab may be considered for postmenopausal women with hormone receptor-positive breast cancer who have progressive bone loss despite other treatments. However, confidence in this recommendation is LOW because the evidence comes from a small case series. Larger prospective studies are needed before this becomes standard practice. Patients should discuss romosozumab with their oncologist and bone specialist as a potential option, not as a proven first-line treatment.
This research is most relevant to postmenopausal women with hormone receptor-positive breast cancer who are taking aromatase inhibitor therapy and experiencing bone loss or fractures. It may also interest their oncologists and bone health specialists. Women with other types of cancer or men with cancer-related bone loss should not assume these findings apply to them without further research.
In this study, bone density improvements were measured after 12 months of treatment. Patients would likely need to continue treatment for at least this long to see meaningful benefits. The study followed patients for an average of 38 months total, so longer-term safety data is still being gathered.
Frequently Asked Questions
Can romosozumab help breast cancer patients with weak bones from treatment?
Preliminary evidence suggests yes—a 2026 study of 22 women showed spine bone density increased 11.5% and hip density increased 4.1% after 12 months. However, larger studies are needed to confirm effectiveness and long-term safety in cancer patients.
Does romosozumab increase cancer recurrence risk in breast cancer patients?
In this small 22-patient study, no cancer recurrence occurred during 38 months of follow-up, and cancer markers remained stable. However, the sample size is too small to definitively rule out rare risks, and more research is needed.
How long does it take to see bone strength improvements from romosozumab?
In this study, significant bone density improvements were measured after 12 months of treatment. Patients would likely need to continue treatment for at least this duration to see meaningful benefits in bone strength.
Who should consider romosozumab for cancer-related bone loss?
Postmenopausal women with hormone receptor-positive breast cancer experiencing progressive bone loss or fractures despite other treatments may be candidates. Discuss with your oncologist and bone specialist whether this drug is appropriate for your specific situation.
Is romosozumab better than other bone-strengthening drugs for cancer patients?
This study didn’t compare romosozumab to other treatments, so we can’t say it’s definitively better. It works differently than common bone drugs by stimulating bone formation, which may help some patients whose bones continue weakening despite other medications.
Want to Apply This Research?
- Track bone density measurements (DEXA scan results) every 12 months, recording spine and hip bone density percentages. Also monitor fracture incidents and any bone-related pain or mobility changes.
- If prescribed romosozumab, set monthly reminders for injections and daily reminders for calcium and vitamin D supplements. Log any falls or injuries to catch potential fractures early.
- Maintain a timeline of DEXA scan results, medication adherence, fracture events, and cancer marker blood test results. Share this data with both your oncologist and bone health specialist at regular appointments to assess treatment effectiveness.
This research is preliminary and based on a small case series of 22 patients without a control group. These findings should not be considered definitive medical advice. Romosozumab for cancer-related bone loss is not yet standard treatment and requires further research. Anyone considering this medication should consult with their oncologist and bone health specialist to discuss whether it’s appropriate for their individual situation. This article is for educational purposes and does not replace professional medical guidance. Always follow your healthcare provider’s recommendations regarding bone health and cancer treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.